Recombinant mutant human granulocyte colony stimulating factor (rmhG-CSF) was engineered by mutating specific amino acids and adding a cysteine residue at the C-terminal.
The modified rmhG-CSF was pegylated using a PEG-Mal 20000 compound and purified through ion-exchange and gel filtration chromatography, achieving over 95% purity as confirmed by SDS-PAGE analysis.
Bioactivity studies demonstrated that the pegylated rmhG-CSF maintained its full functionality and had a longer half-life in mice compared to traditional pegylation methods.